Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Arena Pharmaceutical (ARNA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 360,110
  • Shares Outstanding, K 243,260
  • Annual Sales, $ 38,330 K
  • Annual Income, $ -107,980 K
  • 36-Month Beta -0.68
  • Price/Sales 9.40
  • Price/Book 88.46

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.37 +2.19%
on 12/02/16
1.67 -16.17%
on 11/15/16
-0.07 (-4.76%)
since 11/07/16
3-Month
1.35 +3.70%
on 11/03/16
1.92 -27.08%
on 10/10/16
-0.15 (-9.68%)
since 09/07/16
52-Week
1.30 +7.69%
on 01/11/16
2.16 -35.19%
on 06/09/16
-0.51 (-26.70%)
since 12/07/15

Most Recent Stories

More News
Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Professor Lucie Clapp will present a poster at the American Heart Association (AHA) Scientific Sessions 2016 on Monday, November 14 at 10:45am...

Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise

Arena Pharmaceuticals, Inc (ARNA) reported a loss of 5 cents per share in the third quarter of 2016, narrower than both the year-ago loss of 11 cents and the Zacks Consensus Estimate of a loss of 7 cents....

Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the third quarter ended September 30, 2016, and provided a corporate update.

Arena (ARNA) Q3 Earnings: Will the Stock Pull a Surprise?

Arena Pharmaceuticals, Inc. (ARNA) is scheduled to report third-quarter 2016 results on Nov 7, after the market closes.

Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin HCl) CIV....

Arena Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Monday, November 7, 2016

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2016 financial results and provide a corporate update on Monday, November 7, 2016, after the...

Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status

TradersNewsSource.com Biotechnology Market News: Two small-cap biotech companies we follow, Dynavax Technologies Corporation (NASDAQ: DVAX) and Celldex Therapeutics (NASDAQ: CLDX), released positive news...

Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status

TradersNewsSource.com Biotechnology Market News: Two small-cap biotech companies we follow, Dynavax Technologies Corporation (NASDAQ: DVAX) and Celldex Therapeutics (NASDAQ: CLDX), released positive...

Biotech Stocks on Investors' Radar -- Arena Pharma, Progenics Pharma, Sangamo Biosciences, and Alnylam Pharma

As the US markets see some broader gains in yesterday's session, with five out of nine sectors ending in positive, Stock-Callers.com review the following Biotech stocks: Arena Pharmaceuticals Inc. (NASDAQ:...

Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Support & Resistance

2nd Resistance Point 1.51
1st Resistance Point 1.45
Last Price 1.40
1st Support Level 1.37
2nd Support Level 1.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.